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Fetuses Exposed to Maternal Anti-Ro/SSA and Anti-La/SSB
Antibodies Did Not Predict Progressive Heart Block
A Prospective Observational Study on the
Effects of Maternal Antibodies on 165 Fetuses
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Objectives We prospectively examined the prevalence and outcome of untreated fetal atrioventricular (AV) prolongation in
the presence of maternal anti-Ro antibodies.
Background It has been suggested that antibody-mediated congenital complete atrioventricular block (CAVB) may be preventable
if detected and treated early when low-grade block is present. With this rationale in mind, dexamethasone has been
advocated by others to treat prolonged fetal AV conduction 2 z-scores, consistent with first-degree heart block.
Methods Between July 2003 and June 2009, 165 fetuses of 142 anti-Ro/La antibody–positive women were referred to
our center for serial echocardiography. Our protocol included weekly evaluation of the fetal AV conduction be-
tween 19 (range 17 to 23) and 24 (range 23 to 35) gestational weeks. AV times were compared with institu-
tional reference data and with post-natal electrocardiograms.
Results Of 150 fetuses with persistently normal AV conduction throughout the observation period, a diagnosis of CAVB was
subsequently made in 1 at 28 weeks, after the serial evaluation had ended. Of 15 untreated fetuses either with AV
prolongation between 2 and 6 z-scores or with type 1 second-degree block, progressive heart block developed in none
of them. Three of these 15 fetuses (20%) had a neonatal diagnosis of first-degree block that spontaneously resolved
(n  2) or has not progressed (n  1) on follow-up examinations. No other cardiac complications were detected.
Conclusions Fetal AV prolongation did not predict progressive heart block to birth. Our findings question the rationale of a
management strategy that relies on the early identification and treatment of fetal AV prolongation to prevent
CAVB. (J Am Coll Cardiol 2011;57:1487–92) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.12.014Irreversible fetal complete atrioventricular block (CAVB)
related to maternal anti-Ro/SSA autoantibodies typically
develops between 20 and 24 weeks of gestation. The
condition may be preventable if the causative disease process
is detected and treated with maternally administered dexa-
methasone at an early stage (1–4). This implies that
autoantibody-mediated CAVB does not suddenly develop,
but rather represents a progressive condition from first-
degree atrioventricular block (AVB1) or second-degree
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2010, accepted December 13, 2010.atrioventricular block (AVB2). Serial echocardiography of
anti-Ro antibody–exposed fetuses during the period of
highest risk of heart block is increasingly offered as a
strategy to prevent CAVB. Nevertheless, there is contro-
versy about the relevance of newly discovered, more subtle
cardiac manifestations that perhaps relate to antibody-
mediated inflammation. AVB1, diagnosed in 3% to 25% of
exposed fetuses, resolved in most fetuses with or without
steroid treatment (5–7), whereas progression to CAVB has
only rarely been reported (7,8). The aims of this prospective
study were to evaluate anti-Ro antibody–mediated effects on
the fetal heart and develop recommendations that may be
used to manage incomplete atrioventricular (AV) block.
Methods
Between July 2003 and June 2009, 142 anti-Ro antibody–
positive women with 165 fetuses were prospectively exam-
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Antibody-Induced Fetal Heart Disease March 29, 2011:1487–92ined by serial fetal echocardiog-
raphy with GE Vivid-7 (GE
Medical Systems, Horten, Nor-
way) and Philips iU22 (Philips
ATL, Bothell, Washington) ul-
trasound systems. Our protocol
recommended weekly examina-
tions between 19 and 24 weeks
and until about 35 weeks if a
previous child had CAVB. AV
chronology was evaluated by si-
multaneous pulsed Doppler of
the superior vena cava/aorta
(SVC/aorta; N  165; 737 ex-
aminations) and left ventricular
inflow/outflow tracts (in/out;
n  165; 737 examinations). AV
intervals were measured from the
onset of the A-wave to the be-
ginning of the aortic flow wave. Right ventricular tissue
Doppler imaging (TDI) (178 examinations) was used for
first 39 study fetuses and thereafter to confirm AV block.
TDI-derived AV intervals were measured from the onset of
late diastolic wall motion (A=) to the onset of the isovolu-
metric ventricular contraction spike (IV). Averaged AV
times from 3 to 5 cardiac cycles were compared with
institutional reference data (9). Post-natal examinations at 4
to 6 weeks of age included 12-lead electrocardiography. In
accord with other studies, AV/PR intervals 2 z-scores
ere considered prolonged (6,7,10). The study was ap-
roved by our ethics board.
tatistical analysis. Results are expressed as median
range), mean  SD, frequencies, or z-scores. Linear
egression adjusted for repeated measures was used to
valuate the effect of gestational age on AV duration.
ne-way analysis of variance was used to compare post-
atal PR with fetal AV duration. Analyses were performed
sing SAS statistical software version 9.2 (SAS Institute,
ary, North Carolina).
esults
total of 737 echocardiograms were performed with a
edian of 4 (range 2 to 12) examinations between 19 (range
7 to 23) and 24 (range 23 to 36) weeks. None of the 165
etuses had bradycardia 120 beats/min, endocardial fibro-
lastosis, effusions, or cardiac dysfunction. Figure 1 shows
he age-adjusted AV durations.
Normal AV times2 z-scores were found in 150 fetuses.
ne fetus (fetus 1 in Figs. 1D and 1E) had normal findings
n 3 echocardiograms to 24 weeks when no further evalu-
tion was planned. CAVB with a ventricular rate of 62
eats/min was diagnosed at 28 weeks. The child is clinically
ell and without a permanent pacemaker at age 4 years.
Abbreviations
and Acronyms
AV  atrioventricular
AVB1  first-degree
atrioventricular block
AVB2  second-degree
atrioventricular block
CAVB  complete
atrioventricular block
in/out  left ventricular
inflow and outflow pulsed
Doppler echocardiography
SVC/aorta  superior vena
cava and ascending aorta
pulsed Doppler
echocardiography
TDI  tissue Doppler
imaginglectrocardiograms showing sinus rhythm (148  17 beats/ rin) with normal PR intervals (97  8 ms) were obtained
n 116 other fetuses at 49 (range 5 to 309) days of life.
Transient AV prolongation 3 z-scores was detected in
1 fetuses (7%) by SVC/aorta (10 of 737 examinations),
n/out (8 of 737 examinations), and/or TDI (4/178 exam-
nations). Eight of them had AV prolongation by 2 imaging
odalities during the same (n  5) or different (n  3)
isits. Without dexamethasone treatment, 10 of 11 had
ormal electrocardiographic findings at 56 (range 43 to 87)
ays of life, showing sinus rhythm (150  20 beats/min)
nd normal PR durations (102  13 ms). The exception is
now 6-year-old girl with transient AVB1 (PR duration
32 ms) at 1 month.
Persistent AV prolongation 3 z-scores to birth was
etected in 3 fetuses (2%) (fetuses 2 to 4 in Figs. 1D and 1E)
hat without dexamethasone did not progress. In fetus 2,
here were normal findings on examination at 20 weeks.
wo weeks later, the AV intervals were prolonged (SVC/
orta: 150 ms; z-score 4.1; in/out: 165 ms; z-score 5.4; TDI:
25 ms; z-score 4.8). A healthy girl was delivered at 32
eeks for maternal reasons. AVB1 (PR 152 ms) was
onfirmed by neonatal electrocardiography and persists at
ge 3 years (PR 190 ms; z-score 5.9). Fetus 3 had AV
rolongation from 22 weeks to delivery (SVC/aorta: 144 to
62 ms; z-scores 3.3 to 4.7; in/out: 150 to 164 ms; z-scores
.5 to 4.6; TDI: 136 ms at 32 weeks; z-score 3.6) but
ormal electrocardiographic findings at birth (PR 118 ms)
nd 2 months (114 ms). Fetus 4 (Fig. 2), when first seen at
2 weeks, had persistent AV prolongation (SVC/aorta: 144
o 160 ms; z-scores 3.4 to 4.8; in/out: 148 to 170 ms;
-scores 3.5 to 5.7; TDI: 123 ms at 22 weeks; z-score 4.6).
R intervals were borderline prolonged at birth (128 ms)
nd normal at 6 months (138 ms).
Mobitz type 1 AVB2 was seen in a fetus at the 24-week
xamination (Fig. 3) but resolved the next day. At day 2 of
ife, transient 2:1 AV block in association with QTc
rolongation (0.49) was detected, but there were normal
lectrocardiographic findings (PR 128 ms; QTc 0.43) at 3
onths.
Figure 4 illustrates the relationship between fetal AV
uration and PR duration in early infancy. PR intervals in
etuses with normal or transiently prolonged AV conduction
ere shorter compared with fetuses with persistent AV
rolongation 3 z-scores to birth.
In summary, progressive heart block developed in none of
5 untreated fetuses with AV prolongation. This results in
% sensitivity and 91% specificity in predicting CAVB by
erial echocardiography when 2 z-scores are used for the
bnormal AV interval range.
iscussion
urrently there are no standard guidelines for the surveil-
ance of autoantibody-exposed fetuses nor is there consensus
egarding whether/when AV prolongation should be
b
m
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March 29, 2011:1487–92 Antibody-Induced Fetal Heart Diseasetreated. A different screening protocol and treatment indi-
cation (3,5–7) were used in 4 recent studies. Friedman et al.
(5) and Rein et al. (6) treated with maternal steroids if the
fetal AV interval exceeded 3 z-scores by in/out or 2 z-scores
Figure 1 Fetal AV Time Intervals of the Study Cohort
The echocardiographic atrioventricular (AV) intervals of 161 fetuses without (A to
against normal values (9). The lines denote the 2 z-score (2.5%; 97.5%; dashed
showed no differences between reference values and AV times of fetuses without
echocardiography (A, n  161), left ventricular inflow and outflow pulsed Doppler
remaining fetuses, persistent AV time abnormalities had developed to birth reveal
and left ventricular inflow and outflow pulsed Doppler echocardiography (E). This i
28 weeks’ gestation, fetus 2 with persistent fetal and post-natal first-degree AV bl
prolongation. GA  gestational age.y TDI. We were reluctant to use this approach for 2 areasons. First, the 95% limit of observer variability in AV time
measurement is 1 z-score (10 ms) for SVC/aorta, 1.5
z-score (12 ms) for TDI, and almost 2 z-scores (17
s) for in/out (9). It may therefore be possible to diagnose
4 fetuses with (D and E) persistent AV prolongation to birth are shown, plotted
nd 3 z-score (99.7%; solid line) confidence limits. Regression analyses
tent AV prolongation by superior vena cava and ascending aorta pulsed Doppler
rdiography (B, n  161), and/or tissue Doppler imaging (C, n  39). In the 4
superior vena cava and ascending aorta pulsed Doppler echocardiography (D)
s fetus 1 with normal AV conduction to 24 weeks but congenital AV block after
hereas fetuses 3 and 4 have normal AV conduction despite persistent fetal AVC) and
line) a
persis
echoca
ed by
nclude
ock, wnd treat mild AV prolongation when the electrical PR
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Antibody-Induced Fetal Heart Disease March 29, 2011:1487–92duration is normal. Second, progression had been reported
in only 2 cases (7,8). The first case had AV prolongation of
3 z-score at 19 weeks and CAVB 6 days later. The second
case had fetal hydrops when AV prolongation of 3 z-score
developed at 22 gestational weeks, followed by CAVB and
demise despite steroid treatment. In contrast, in 24 similar
cases reported in the literature, the fetuses did not progress
to CAVB (2,3,5–7,11–14). Four steroid-treated fetuses
with AV prolongation 190 ms had first or first-to-second
Figure 2 Fetus With Persistent AV Prolongation
This untreated fetus (fetus 4) was diagnosed with fetal atrioventricular (AV) prolon
echocardiography (A), superior vena cava and ascending aorta pulsed Doppler ech
months, the PR duration was normal (D).
Figure 3 Fetus With Type 1 AVB2
Superior vena cava and ascending aorta pulsed Doppler echocardiography of this
tricular block (AVB2) with progressive atrioventricular (AV) interval lengthening from
child also had brief neonatal 2:1 AV block (not shown).degree AVB after birth (2,3,13). Nine other fetuses had
shorter AV prolongation (2.3 to 5.5 z-scores) that rapidly
resolved with dexamethasone (5,6,14). Nonetheless, spon-
taneous resolution was also seen in 11 untreated fetuses with
AV intervals 3 z-scores (7,11). These data show that
resolution, progression, or nonprogression can occur with
and without treatment and highlight the need for a prog-
nostic marker that could reliably distinguish benign or
false-positive AV prolongation from true AV nodal disease.
3 z-scores at 22 weeks by left ventricular inflow and outflow pulsed Doppler
iography (B), and tissue Doppler imaging (C) that persisted to birth. At 6
t 24 gestational weeks shows transient Mobitz type 1 second-degree atrioven-
ms (yellow) to 175 ms (green) and normal post-block AV interval. The samegation
ocardfetus a
130
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March 29, 2011:1487–92 Antibody-Induced Fetal Heart DiseasePrevalence and relevance of AV prolongation. We ob-
served similar proportions of fetuses with AV prolongation
to that reported by Rein et al. (6) (2 z-score: 9% vs. 9%)
and by Friedman et al. (5) in the PRIDE (PR Interval and
Dexamethasone Evaluation Study) (3 z-score: 2% vs.
1.8%) and experienced comparable outcomes, albeit without
the use of dexamethasone. The only fetus with a major
autoantibody-related complication in this study was not
identified because CAVB developed after the usual obser-
vation period according to our protocol. Although this case
demonstrates that CAVB can develop later in pregnancy,
it is uncertain that, in the absence of sensitive and specific
early predictors of progressive conduction disease, more
extensive surveillance (e.g., to 28 weeks) would have
prevented the only case of this condition. Most affected
fetuses in other prospective studies had normal AV
intervals before the detection of CAVB (5,7,11,12),
suggesting that CAVB results from a rapidly evolving
inflammatory process that may not initially manifest with
incomplete AV block. Conversely, despite significant AV
prolongation to 6 z-scores in some cases, CAVB did not
develop in any of our 15 fetuses, and only 1 child has mild
AVB1 beyond infancy. This includes a fetus with Mobitz
type 1 AVB2. A similar arrhythmia has been reported
only once before in an anti-Ro antibody– exposed fetus
with endocardial fibroelastosis and pericardial effusion.
After administration of maternal dexamethasone, the
child was born with AVB1 (4). In contrast, our patient
had isolated, transient fetal and neonatal AVB2, probably
related to perinatal QT interval prolongation. Transient
QTc prolongation, although usually less significant, has
been reported in otherwise asymptomatic infants born to
mothers with anti-Ro antibodies (15). In our case, the
finding of neonatal 2:1 AV block prompted the neonatal
treatment with a beta-blocker until the genetic workup
Figure 4 Box Plots Comparing Fetal AV Intervals
With Neonatal PR Durations
Atrioventricular (AV) prolongation 3 z-scores was associated with longer
neonatal PR intervals compared with fetuses with no (2) or mild (2 to 3)
AV prolongation.excluded long QT syndrome.Study limitations. Thirty-three fetuses (20%) with normal
AV conduction were not referred for a post-natal examina-
tion. All are reportedly healthy and had normal heart rates
at birth and thereafter according to their physicians. This
likely precludes undetected CAVB.
Conclusions
Fetal AV prolongation was not predictive of CAVB but
spontaneously resolved in all but 1 fetus with persistent
mild AVB1. Without severe PR prolongation, AVB1 is
considered a benign condition without risk of progressive
conduction disease (16). Whether a distinct z-score value
in AV duration predicts progressive heart block remains
an important question. We suggest that transplacental
treatment should be restricted to those fetuses with
progressive AV block or with additional findings of
autoantibody-mediated pathology, such as endocardial
fibroelastosis and effusions (4,5,8,13). In contrast, in
isolated AV prolongation up to 6 z-scores, close moni-
toring for disease progression without treatment is rec-
ommended. The utility of this approach needs confirma-
tion in a large prospective, multicenter study.
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